Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Shareholder Meeting (October 2022)
14 slides from Oncosil Medical's shareholder meeting presentation, Oct 25, 2022
Slide 1: CEO AGM Presentation
CEO AGM Presentation 25 October 2022
Slide 2: Introduction
Introduction The prognosis for pancreatic cancer patients has remained almost unchanged for over 40 years1 with a reported five-year survival rate for the disease of 10%2 Changes in survival, 1971-72 to 2010-11 0% 25% 50% 75% 100% All Cancers Incidence Testis Malignant Melanoma Prostate Hodgkin Lymp
Slide 3: OncoSil Medical's targeted approach delivers a positive impact in pancreatic cancer
OncoSil Medical’s targeted approach delivers a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients 3 • CEO AGM Presentation • 25 October 2022
Slide 4: Board and Management Team with Experience and Expertise
Board and Management Team with Experience and Expertise Otto Prof Brian Buttula Ricky Sharma Leedman Non-executive Non-executive Non-executive Chairman Director Director Extensive experience in International authority on Experienced company director, investment research, funds translation of radiobi
Slide 5: OncoSil Device
OncoSil™ Device Overview • OncoSil™ is intended for the treatment of locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. • OncoSil™ is a single-use brachytherapy device comprised of microparticles and a diluent. • OncoSil™ is implanted directly into a
Slide 6: Oncosil Device Animation
Oncosil Device Animation 6 • CEO AGM Presentation • 25 October 2022
Slide 7: What we have accomplished
What we have accomplished Experienced CE Marking Innovation Funding Enabled HDE pathway team in place obtained (NUB) approved for bile duct cancer German funding in the US of the OncoSil™ device Application submitted to FDA PanCO Study Breakthrough device Current market approvals completed designati
Slide 8: Surgical Resection remains the gold standard
Surgical Resection remains the gold standard The only potentially curative treatment for pancreatic cancer1 RESECTABLE LOCALLY ADVANCED METASTATIC % of patients at diagnosis 15% 30% 55% Surgical resection with Palliative therapies Palliative therapies curative intent (CT or ICT/CCRT)1,7,8 (usually C
Slide 9: PanCO results showing compelling evidence of downstaging
PanCO results showing compelling evidence of downstaging OncoSil™ converted patients with unresectable locally advanced pancreatic cancer (LAPC) to resection, transforming their prognosis and substantially extending survival What did the PanCO study show? ≥32 months Adding OncoSil™ to 1 in 3 patient
Slide 10: Sales and training activities to date
Sales and training activities to date During the year, the OncoSil™ team has progressed on key site start-up activities Key experienced sales, marketing and training team in place OncoSil™ launched in: – no need for any expansion of the team in the near term Distributors have been identified in othe
Slide 11: This is where we are today
This is where we are today Market access and clinical development supporting sales activities Sales team fully Detailed health Identifying programs Clinical Development Ongoing dialogue engaged with economic and market for fully funded, pathway with the FDA on the targeted Key Opinion access analysi
Slide 12: FY 2023 Impending Deliverables
FY 2023 Impending Deliverables 1. Accelerate commercial sales of the OncoSilTM device. 2. Pursue additional reimbursement programs. 3. Geographic expansion of sales. 4. Expand authorised user base. 5. Expand clinical data. 6. Progress FDA discussion for HDE in dCCA (distal cholangiocarcinoma). 7. Di
Slide 13: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 14: Nigel Lange
Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com OncoSil Medical Ltd www.oncosil.com T: +49 160 9642 4981